Galy, a Boston biotech better known for lab-grown cotton, began selling cell-cultured cocoa to professional kitchens on 20 October 2026 under a brand called WunderHaus. The product is a couverture and baking chocolate. Galy’s chief executive says the current products “combine Galy cocoa with conventionally sourced cocoa ingredients”, so what a chef buys is a blend. Galy has not published the blend ratio, a volume, a price per kilogram or a production capacity.
That silence is the story, because Galy is not an outlier. Across the five companies we could find working on cell-cultured cocoa, exactly one has put a capacity number in public, and it is a rival’s: California Cultured said in March that “the capacity over the next year will be at 160,000 litres”. It is a volume of tank, not a mass of cocoa, and nobody in the category has published the yield that would convert one into the other.
This piece sets out what each company has actually disclosed, what regulatory position each has taken, and what a buyer can and cannot work out from it. It does not assess taste, and it does not assume the technology works at scale. The question is narrower: what would you need to know to place an order, and which of it is missing?
Method and limits
We read every source listed below in full, and used a number only where a fetched page states it. We searched the FDA’s GRAS Notice Inventory for “cocoa”. We did not find a company’s own filing documents for any of the cell-cultured cocoa notices, so every statement about a company’s regulatory filing rests on what that company told a journalist. Where a claim is a company’s own, the text says so.
What Galy has said, line by line
The Green Queen report, published 20 October and updated 21 October, is the fullest account. Galy was founded in 2019 by Luciano Bueno and Paula Elbl. Production starts from a small piece of cocoa bean whose cells are multiplied in brewery-style tanks; the harvested material is then fermented and roasted outside the tanks and ground into cocoa powder. Galy says it repurposed existing infrastructure in Essex, Massachusetts for the work, and that it went from lab to commercial scale in “less than one year”. About 80% of the cocoa process is shared with its cotton platform, which is the most plausible explanation for that speed, though Galy does not draw the link in the sources we read.
| Item | What Galy says | What is missing |
|---|---|---|
| Product | Couverture and baking chocolate for professional kitchens | Blend ratio of Galy cocoa to conventional cocoa |
| Site | Repurposed existing infrastructure in Essex, Massachusetts | Tank size, number of vessels, output |
| Price | “Comparably” priced to conventional premium chocolate in that segment | Any price per kilogram or per tonne |
| First customer | Troquet on South, Boston, which placed one of the first purchase orders | Order size |
| Second customer | An unnamed Dubai-based chocolatier, initial purchase order | Name, size |
| US regulatory | Self-affirmed GRAS; FDA notified of the assessment; “no questions” letter sought | Any FDA response |
| UAE | Applied to ADAFSA, targeting 2027 | Review timeline |
| EU | “Considering” novel food authorisation for 2027–28 | Whether an application exists |
| Environmental | “Around 80% or more” lower resource use, preliminary | No life-cycle assessment completed for cocoa |
One figure in the coverage looks like a price and is not: a $250 three-course menu at Troquet on South. That is the cost of a meal, not of the chocolate in it.
Practical consequence: a buyer cannot cost a WunderHaus formulation. “Comparable to premium chocolate” tells a chef the product will not be a luxury surcharge, but it gives a formulator nothing to model, and the blend ratio determines how much of any flavour or sustainability claim the finished product can honestly carry.
Two accounts of the launch date
The sources disagree on timing. NOSH reports that Galy launched WunderHaus in October 2026 and that more restaurants will add menu items “this winter”. Green Queen says the US launch is in December 2026, in a hybrid format at Troquet on South, with other restaurants and hotels testing the product for winter menus. These are reconcilable if “launch” means first orders in October and a public menu in December, but neither source says so. We have not resolved it.
The regulatory position: self-affirmed, notified, unanswered
Galy says it has self-affirmed its cocoa powder as generally recognised as safe and has notified the FDA of its assessment, seeking a “no questions” letter. California Cultured described the same two-step position in March: it self-affirmed GRAS for its cell-based cocoa powder and also submitted a GRAS notice to the FDA, again seeking a “no questions” letter. Green Queen’s report gave no GRN number and no FDA response.
We searched the FDA’s GRAS Notice Inventory for “cocoa” on 25 October. It returned 11 records, none described as cell-cultured or plant-cell-derived. The closest is GRN 947, cacao pulp and cacao fruit juice concentrate, closed in December 2021 with “no questions”. That absence proves little by itself: a notice submitted this year may not yet be visible, or may be indexed under a different substance name, and we did not open the detail pages. What it does establish is that, as of this week, a reader cannot go to the public record and read any cell-cultured cocoa safety dossier. The regulatory claims in this category are, today, company statements.
The route also matters because it is moving. FDA’s proposed rule on substances generally recognised as safe, published in the Federal Register on 11 August 2026 (91 FR 51834, docket FDA-2025-N-3262), would make notification of an independent GRAS conclusion mandatory, subject to listed exceptions, and offers a time-limited streamlined submission for certain intended uses of substances already on the market. Comments are due by 9 December 2026. We have not read the final sections of the proposal that fix effective and compliance dates, so we do not state them. Our analysis of what the proposed rule does to self-affirmed conclusions covers the mechanics, and our piece on Better Dairy’s lactopontin shows the same self-affirm-first sequence in a different product.
Practical consequence: for a chocolate manufacturer’s regulatory team, “self-affirmed and notified” is an assertion that the supplier’s own panel is satisfied. Whether to accept that, or to wait for an FDA response, is a supplier-qualification decision. If the proposed rule is finalised in anything like its current form, today’s self-affirmed position would need to be put in front of FDA anyway.
The category, company by company
| Company | Position on record | Capacity or scale disclosed | Price disclosed | Timing stated |
|---|---|---|---|---|
| Galy | Self-affirmed GRAS, FDA notified (October 2026) | None; repurposed Essex, MA site | None; “comparable” to premium chocolate | US launch December 2026; UAE 2027; EU 2027–28 considered |
| California Cultured | Self-affirmed GRAS plus GRAS notice (March 2026), no FDA response reported | 160,000 litres over the next year; 12,000 sq ft West Sacramento facility; uses Pow.Bio’s 25,000 sq ft facility for scale-up | None; “price-competitive with supermarket chocolate” | Ingredient launch “later this year”; Puratos product by end of 2026 |
| Puratos (customer, with California Cultured) | Product in development for professionals | None | None | Fully available to US customers by end of 2026 |
| Kokomodo (Pluri), with Cargill | Not yet filed; plans a submission in 2026 | None | None; aiming for “commercially viable pricing” | Products “as early as 2027” |
| Barry Callebaut | Partnership with Zurich University of Applied Sciences announced in summer 2025 | None | None | None |
The single quantified capacity is California Cultured’s. Alongside it the company projected a 76% operating margin on its first product at that capacity, and said it had raised about $15.9 million to date and was in the market raising a Series A3. Those are company projections reported in one article, and the margin has no stated price or cost behind it. Without a yield per litre, 160,000 litres cannot be turned into tonnes of cocoa powder, so even this one figure cannot be compared with a supplier quoting tonnes.
California Cultured has also described its route to lower cost: the Food Institute reports it is moving to reusable plastic bioreactors, and Green Queen reports the company’s view that plant-cell culture needs less spending on media, R&D, capex and bioreactors than cultivated meat or precision fermentation. That is a cost-structure claim, not a cost.
Practical consequence: the only defensible comparison between suppliers today is on regulatory posture and launch timing. Capacity and price cannot be compared, because only one supplier has given a capacity and nobody has given a price.
The benchmark these products are being sold against
The reason there is a market is the price of the thing being replaced. Trading Economics reported cocoa futures at around $5,640 a tonne on 7 October 2026, caught between ample current supplies and a deteriorating outlook for the 2026/27 season tied to El Niño. Ivory Coast’s main crop was expected to fall about 17% this season. The same page records a fall of 5.01% on 22 October to $5,550.53 a tonne. NOSH adds that average cocoa prices are still more than double their level four years ago.
For scale, $5,640 a tonne is $5.64 a kilogram. That is a bean futures price, not the price of cocoa powder or couverture chocolate, which carry processing and margin on top, so it is a floor for the comparison and not the comparison itself. The point is narrower: the incumbent’s price is public, daily and volatile, and the challenger’s price is nowhere. A buyer pricing a hedge against cocoa volatility cannot tell what the hedge costs.
The counter-argument
The case for reading this charitably is reasonable. Early commercial sales in a B2B foodservice channel are often priced by negotiation and kept private, and a chocolatier trialling a blend does not need a published price list. Galy’s route of selling first to restaurants and hotels, with no retail plans yet, is a way to learn the process while volumes are small. A company that repurposed an existing site in under a year may simply have little capacity to disclose. And nothing here says the regulatory position is weak; the self-affirmed route is the one the FDA’s proposed rule would change rather than one it has already closed, and two of these companies say they have also notified FDA.
All of that can be true and the buyer’s problem remains. Consumer acceptance is also unresolved: the Food Institute quoted Glanbia’s Oshin Sahni saying people “don’t seem to be happy about eating cell-cultured chocolate”, citing concerns about artificiality. That is one executive’s view, but it bears on the labelling and blending decisions that Galy has not yet explained. For the adjacent cocoa-free route, where products are already on shelves, see our report on Aeon’s listings of Planet A Foods and Fuji Oil products.
What we could not establish
- The blend ratio in Galy’s current products, and whether any WunderHaus product is labelled as containing cell-cultured cocoa.
- Any volume, capacity, price or order size for Galy, including the Dubai chocolatier’s order.
- Whether FDA has responded to Galy’s or California Cultured’s notices. We found no record in the FDA inventory search for “cocoa”, and could not confirm filing dates or notifier names from the page we read.
- The conversion from California Cultured’s 160,000 litres to a mass of cocoa powder. No source gives a yield.
- Whether Galy launched in October or launches in December. NOSH and Green Queen differ, as set out above.
- The reliability of Galy’s environmental estimate. It is preliminary and Galy says no cocoa life-cycle assessment has been completed.
- The effective and compliance dates of FDA’s proposed GRAS rule. We did not read that part of the document.
What to watch
- An FDA response letter, or a visible GRN, for either Galy or California Cultured. Either would be the first public safety record in the category.
- Whether any company publishes a price per kilogram or a yield per litre. Until one does, capacity claims cannot be compared.
- Puratos’s end-of-2026 commercial availability: whether the product ships, and whether it states the cell-cultured cocoa content.
- Kokomodo’s planned 2026 regulatory submission, and whether it is a notice or a self-affirmation.
- The outcome of the 9 December comment deadline on FDA’s GRAS proposal, and what it does to products that rely on a self-affirmed conclusion.
- Galy’s December Troquet on South menu, and any additional named customers.